Should You Buy Elevance Health Stock For The Margin It Lost?
Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.
Why Is Elevance Health Keeping Less Of Each Revenue Dollar?
Revenue over the trailing twelve months reached $201 billion, up 6.3% and in line with its three-year pace, though operating revenue in the June 2026 quarter rose just 0.8% year over year as health plan membership fell. Net margin has thinned: 2.5% over those twelve months, against a three-year average of 3.2%. That gap is the upside case.
Part of that gap has an address. The company’s full-year 2026 outlook for its Medicaid operating margin is approximately -1.75%, and the costs behind it are named: behavioral health, specialty pharmacy, outpatient surgery and emergency department use. Management says acuity has not stepped up again, and that the added pressure increasingly comes from how much care the members who stay are using.
Can Elevance Health Repair Medicaid The Way It Is Repairing Medicare Advantage?
Medicare Advantage is the receipt. For 2026 the company rebuilt that book on purpose, with tighter plan design and a narrower product mix weighted toward D-SNP and HMO plans. Helped by favorable claims experience, that business is on a path to an operating margin of at least 2% in 2026, and management credits it with about half of the June 2026 quarter’s operating outperformance against the company’s own expectations.
Medicaid is the same discipline, a year behind. Elevance Health has agreed to exit the D.C. Medicaid market and expects to leave more Medicaid markets over the next 12 to 18 months where it sees no path to sustainable performance. July 2026 rate updates arrived in the mid-single-digit percent range, better than the company assumed at the start of 2026. Management calls 2026 the trough for the Medicaid margin.
Do You Need Medicaid To Turn Before You Buy ELV?
The guidance does not need it. The upside does. Management’s raised 2026 adjusted earnings-per-share guidance of at least $27 rests on Medicare Advantage and individual ACA, not on Medicaid. The company holds to at least 12% adjusted earnings growth in 2027 off a lower 2026 baseline of at least $26 a share.
The stock has cleared 30% inside two months on seven occasions since 2010, twice topping 50%, and it trades about 7% below its 52-week high.
Medicaid rates came in higher than expected and acuity behaved, yet the margin outlook did not move. Management points to timing, the part of the book the July 2026 rates touch, and elevated utilization. The question is whether the unchanged outlook reflects prudence or a trend worse than it looks. The second half of 2026 decides which. Management already expects the Medicaid margin to improve from the June 2026 quarter, so watch whether it beats the full-year outlook.
The same test applies to every company promising a better 2027. Our guidance-driven momentum screen ranks them on whether the guidance is actually moving up.
How Much Of Your Wealth Should One Opportunity Carry?
Spotting an opportunity is the enjoyable half of investing, and deciding how much of your net worth rides on it is the half that compounds. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.